Biopharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for the Investigational New Drug (IND) application to assess VTR-297 intended for the treatment of onychomycosis, a fungal infection of the nail.
VTR-297 is a small molecule histone deacetylase (HDAC) inhibitor with activity against dermatophytes and fungi, originally isolated from the yeast species Streptomyces hygroscopicus as an antifungal antibiotic, first described in 1976.
Mihael H Polymeropoulos, MD, Vanda's president, CEO and chairman of the board, said: "The initiation of clinical studies with VTR-297 in the treatment of onychomycosis is an important milestone in studying and developing potential new therapies for this common disorder."
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices
hVIVO reports positive results from RSV antiviral human challenge trial
Amyris enters agreement with BioMaP-C
Avidity Biosciences reports partial clinical hold on delpacibart etedesiran lifted
UroGen Pharma doses first patient in Phase 3 trial of UGN-103 for bladder cancer
Brain+ launches Ayla CST Assistant following UK regulatory approval
Advicenne's ADV7103 achieves regulatory milestones in the US
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Johnson & Johnson submits DARZALEX FASPRO supplemental Biologics License Application to FDA
Modalis Therapeutics receives FDA Rare Pediatric Disease designation for MDL-101 in LAMA2-CMD
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
Astria Therapeutics secures FDA Orphan Drug Designation for Nnavenibart in HAE treatment